UnitedHealth trims drug coverage, including Sanofi insulin
- Top 10 News for 9/26 - 9/30: Deutsche Bank Soars on Settlement; Twitter Back in the M&A Fray; Nike 'Just Didn't Do It' in Q1
- Wall Street rallies, led by Deutsche Bank, financials
- Viacom (VIAB) Forms Special Committee; Will Explore Potential Combination with CBS (CBS)
- Deutsche Bank (DB) Said Near $5.4B Settlement with U.S. - AFP
- Oil up second straight month on OPEC-fueled rally
A packet of diabetes drug Lantus SoloStar passes along the production line at a manufacturing site of French drugmaker Sanofi in Frankfurt June 5, 2013. REUTERS/Ralph Orlowski
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
(Reuters) - UnitedHealth Group (NYSE: UNH), the largest U.S. health insurer, will stop covering several brand-name drugs as of next year, reinforcing a trend of payers steering prescriptions to lower-priced options.
In a bulletin seeking client feedback by Sept. 28, UnitedHealth said it is changing reimbursement terms for long-acting insulins and will no longer cover Lantus, the main insulin drug sold by Sanofi
The insurer said Basaglar, a cheaper biosimilar insulin sold by Eli Lilly (NYSE: LLY) would be covered as "Tier 1," meaning the lowest out-of-pocket costs for members. Levemir, produced by Novo Nordisk
CVS Health (NYSE: CVS) made a similar move last month to drop Lantus in favor of Lilly's new biosimilar.
Analysts at Jefferies said the sales impact of the United exclusion should be less than that from the CVS move, because the United plan covers around 15 million people while CVS covers 19 million.
Sanofi shares fell more than 1 percent on Thursday after the news but had recovered by 1200 GMT, while Novo was down 1.3 percent.
Sanofi reaffirmed its sales expectations despite the latest exclusion. A spokeswoman said the company was still targeting a decline in diabetes drug sales of 4 to 8 percent a year until 2018.
"We are disappointed with the decision. For Sanofi, it is a pity not to leave doctors a choice," she said. "We had anticipated this kind of decision but we are holding discussions with other organisations in the United States to have them keep Lantus on their lists."
Biosimilars are cheaper copies of protein-based biotech drugs such as Lantus, which are no longer protected by patents. They cannot be precisely replicated like conventional chemical drugs but have been shown to be equivalent in terms of efficacy and side effects.
UnitedHealth last year bought Catamaran for $12.8 billion, making it the nation's No. 3 pharmacy benefit manager after Express Scripts Holding (NASDAQ: ESRX) and Caremark, which is owned by CVS.
(Reporting by Deena Beasley, Ben Hirschler and Noelle Mennella; Editing by Ruth Pitchford and Elaine Hardcastle)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Depomed (DEPO) Wins Order Obtaining Injunction vs. Defendants Over Generic Nucynta (AGN)
- Depomed (DEPO) Halted, News Pending
- Regenerx Biopharma (RGRX) JV Commences Second Dry Eye Syndrome-Focused Phase 3 Trial
Create E-mail Alert Related CategoriesCorporate News, FDA, Reuters, Trader Talk
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!